Addex Pharmaceuticals reached the second preclinical milestone in an exclusive collaboration and license agreement with Merck, focused on developing allosteric modulators for treatment of Parkinson’s disease and other undisclosed indications. Addex will receive $500,000 for the second milestone. Using allosteric modulators, this collaboration is focused on developing drugs that specifically activate the metabotropic glutamate receptor 4 (mGluR4). The preclinical study showed the desire...